NVLX Stock UPDATES Nuvilex Inc (NVLX) 0.1788 09/24/2014 06:0

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nuvilex Inc (NVLX) 0.1788 $NVLX

Nuvilex's Partner, Austrianova, Publishes Scientific Review Article Emphasizing Use of Cell-in-a-Box(R) for Treatment of Diabetes
GlobeNewswire - Mon Sep 22, 8:00AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that its partner, Austrianova, published a scientific review in the journal Diabetes Research and Treatment: Open Access. The article addressed the use of cell encapsulation in developing a treatment for type 1 (insulin-dependent or juvenile-onset) diabetes and discussed advantages of using the Cell-in-Box live cell sulfate-based encapsulation technology over other forms of cell encapsulation.

Nuvilex Updates Shareholders on Recent Activities and Discusses Future Plans for Development of Treatments for Cancer and Diabetes
GlobeNewswire - Thu Sep 18, 9:49AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today provides its shareholders with an update on recent activities of Nuvilex and outlines future plans for the development of treatments in the areas of cancer and diabetes. This press release is the version that was to have been published earlier this morning.

Market Maker Surveillance Report. TIVO, MDT, CTSH, RHHBY, NVLX, AMBS, Highest Net Sell Volume and Negative Price Friction For Wednesday, September 17th 2014
M2 - Thu Sep 18, 3:30AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4737 companies with "abnormal" market making, 2409 companies with positive Friction Factors and 2599 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Wednesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. TIVO INCORPORATED (NASDAQ:TIVO), Medtronic Inc (NYSE:MDT), Cognizant Technology Solutions Corp (NASDAQ:CTSH), Roche Holding AG (OTC:RHHBY), Nuvilex Inc (OTC:NVLX), Amarantus BioSciences Inc (OTC:AMBS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Cannabis Support on the Rise as Nuvilex and mCig Move Higher
ACCESSWIRE - Mon Sep 08, 11:01AM CDT
WHITEFISH, MT / September 8, 2014 / Cannabis stocks moved largely lower over the past week amid ongoing profit taking following the industry's run-up over the past year. Top gainers for the week included Nuvilex Inc. (OTC: NVLX) earlier in the week following its application for orphan status for its pancreatic cancer treatment and mCig Inc. (OTC: MCIG) late in the week following the trademarking of two brands.

Nuvilex's Partner, Austrianova, Receives Prestigious Emerging Enterprises 2014 Best Innovation Award in Singapore
GlobeNewswire - Fri Sep 05, 12:22PM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, reported today that its partner, Austrianova, has received the Emerging Enterprises Best Innovation Award for 2014 in Singapore for its innovative Cell-in-a-Box and Bac-in-a-Box cell encapsulation technologies. The award was received at a gala ceremony in Singapore that was hosted by the OCBC bank. The Innovation award was sponsored by SingTel.

Nuvilex Aims for Market Exclusivity with Orphan Drug Status While Eyeing Larger Cancer Market for Cell-in-a-Box Technology
ACCESSWIRE - Fri Sep 05, 8:06AM CDT
New York, NY / ACCESSWIRE / September 5, 2014 / Nuvilex, Inc. (OTCQB: NVLX) has used the last two weeks to further solidify its position as a biotechnology firm, and to further its treatment for advanced pancreatic cancer, as well as, other abdominal cancers. This summer has been a starting line, of sorts, for Nuvilex to begin making the case that Cell-in-a-Box(r) should help it become a competitor in the cancer market.

Nuvilex Submits Application for Orphan Drug Designation to the European Medicines Agency for Its Cell-in-a-Box(R) Treatment for Pancreatic Cancer
GlobeNewswire - Tue Sep 02, 8:58AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has submitted an application to the European Medicines Agency (EMA) for an Orphan Drug Designation for its Cell-in-a-Box treatment for pancreatic cancer. Nuvilex's pancreatic cancer treatment consists of the combination of Cell-in-a-Box with low doses of the anticancer drug ifosfamide. The Cell-in-a-Box portion of the treatment consists of live cells capable of converting ifosfamide into its cancer-killing form that have been enclosed in protective pin-head sized spherical capsules that are composed of bio-inert cellulose.

Nuvilex Begins Preclinical Studies With Translational Drug Development to Determine if Nuvilex's Unique Cancer Treatment Can Slow Accumulation of Malignant Ascites Fluid
GlobeNewswire - Wed Aug 20, 8:29AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that studies are underway at Translational Drug Development's (TD2) facilities in Scottsdale, Arizona, to determine if Nuvilex's unique cancer treatment can slow the accumulation of fluid, known as "malignant ascites," in the abdomen that is characteristic of the growth of many abdominal tumors.

Nuvilex Announces Publication of Combined Results of the Initial Phase 1/2 Clinical Trial and a Second Phase 2 Clinical Trial of the Cell-in-a-Box(R) Plus Ifosfamide Combination in Patients With Advanced, Inoperable Pancreatic Cancer
GlobeNewswire - Thu Aug 14, 8:06AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that its partner, Austrianova, has reported the results from the second Phase 2 clinical trial combining the Cell-in-a-Box cellulose-based live cell encapsulation technology plus low doses of the anticancer prodrug ifosfamide in patients with advanced, inoperable cancer has been published in the scientific journal Pharmaceutics. The title of the publication is "Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious: Data from Two Clinical Trials in Pancreatic Cancer." The entire report can be viewed by clicking http://www.mdpi.com/1999-4923/6/3/447 and then clicking on "Full-Text PDF" on the left side of the page.

Small Business Operations to Large Scale Companies Take Steps to Increase Security Surveillance - Company Selected for Comprehensive Cannabis Security System Installation
PR Newswire - Thu Aug 14, 8:05AM CDT
Security and Surveillance needs become top priority in Cannabis / Legal Marijuana industry as sector continues expansion and growth for the following emerging companies: DirectView Holdings, Inc. (OTC: DIRV), Nuvilex, Inc. (OTC: NVLX), GW Pharmaceuticals plc (NASDAQ: GWPH), Singlepoint, Inc. (OTC: SING) and Cannabis Science, Inc. (CBIS).

Nuvilex Provides Update on Status of Preclinical Studies at Translational Drug Development
GlobeNewswire - Wed Aug 13, 8:00AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it is providing shareholders with an update on the status of Nuvilex's preclinical studies to be conducted by Translational Drug Development (TD2) in Scottsdale, Arizona.

Nuvilex Announces That Dr. Richard M. Hyslop Will Present at the ACS Annual Meeting on "Sustainable, Green Chemistry and Medicine: Targeted Cannabinoid-Based Chemotherapy Utilizing Cell-in-a-Box(R) Live Cell Encapsulation Technology."
GlobeNewswire - Mon Aug 04, 8:46AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Dr. Richard M. Hyslop, Professor of Chemistry and Biochemistry at the University of Northern Colorado (UNC) and member of the Scientific Advisory Board of Nuvilex's subsidiary, Medical Marijuana Sciences, and Dr. Corina Brown of UNC will be presenting at the 248 American Chemical Society National Meeting & Exposition being held in San Francisco, California, August 10-14, 2014. The theme for this year's meeting is "Chemistry and Global Stewardship".

OTC Trading Stock News: Digipath, Inc. Immune Pharmaceuticals, Inc. Vuzix Corp, Nuvilex, Inc. Origin Oil, Inc.
PR Newswire Europe - Tue Jul 29, 7:07AM CDT
LONDON, July 29, 2014 /PRNewswire/ --

Nuvilex Nears Crucial Quality of Life Study in Malignant Ascites Associated with Pancreatic and Other Abdominal Cancers
ACCESSWIRE - Wed Jul 23, 8:01AM CDT
New York, NY / ACCESSWIRE / July 23, 2014 / Nuvilex, Inc. (OTCQB: NVLX) will begin preclinical studies in early August with its Contract Research Organization (CRO) Translational Drug Development (TD2) to study the first of 4 symptoms associated with pancreatic cancer and other abdominal cancers. In what is essentially the biggest step in Nuvilex's history to date, the company will enter the clinic under its own brand for the first time ever, and it will do so with the highly respected oncology CRO, TD2 and its Chief Development Officer, Dr. Daniel Von Hoff. In the studies, Nuvilex and TD2 will determine what effect the company's pancreatic cancer treatment will have on these symptoms.

Cannabis Stocks Edge Higher Last Week Led by Nuvilex & Entertopia
ACCESSWIRE - Tue Jul 22, 8:32AM CDT
WHITEFISH, MT / July 22, 2014 / The Marijuana Index(TM) moved slightly higher last week, despite a 7% drop in GW Pharmaceuticals plc (NASDAQ: GWPH) shares. Medbox Inc. (OTC: MDBX), the second largest component of the index, also fell over 5% last week.

Nuvilex and Austrianova Announce Results of Clinical Trial in Dogs with Mammary Tumors Treated With Cell-in-a-Box(R) Plus Cyclophosphamide
GlobeNewswire - Thu Jul 17, 9:25AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today announced, in cooperation with its partner Austrianova, the results of a veterinary Phase I/II clinical trial in dogs with mammary tumors who were treated with Cell-in-a-Box cellulose-based live cell encapsulation plus the widely used anticancer drug cyclophosphamide (Cytoxan). These results were published in the Public Library of Science journal (PLOS ONE) on July 16, 2014.

Cannabis Stocks Move Higher as Washington State Pot Sales Begin
ACCESSWIRE - Mon Jul 14, 8:30AM CDT
WHITEFISH, MT / July 14, 2014 / The Marijuana Index(TM) moved higher last week in the aggregate, despite a 13% drop in GW Pharmaceuticals plc (NASDAQ: GWPH) shares and a roughly 1.5% drop in Medbox Inc. (OTC: MDBX) shares, which comprise about half of the weighted index.

Nuvilex Provides Shareholder Update on Milestone Accomplishments
GlobeNewswire - Mon Jul 14, 8:01AM CDT
Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today issued the following shareholder update letter from Kenneth L. Waggoner, CEO and President.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Santa Ana Branch Expansion Tests Local Credit Demand

Updated Category News Views 28

A Bigger Room for Smaller Financial Decisions A branch relocation across the same shopping center may sound mundane, but it says plenty about where California Credit Union sees durable demand. The credit union has opened a larger Santa Ana office at 1601 W. 17th Street, Suite C, replacing its prior spot in the same center. This is not some chest-thumping expansion into an...

Continue Reading
Hydron’s Bailey Test Puts RNG Cost Claims to Real Work

Updated Category News Views 15

Landfill gas is messy stuff, which is exactly why Hydron Energy’s Bailey Landfill demonstration in Chilliwack deserves more attention than another clean-energy press release. The British Columbia company is putting its INTRUPTor™ gas-separation system into an operating environment alongside FortisBC and the City of Chilliwack, where the machinery has to deal with real...

Continue Reading
HiTHIUM's 8-Hour Storage Pitch Faces Real Grid Tests

Updated Category News Views 136

Eight hours of stored electricity is where the sales brochure meets the ugly parts of the grid. HiTHIUM arrived at RE+ 2026 in Las Vegas, held November 17 through 19, with a broad storage pitch: systems ranging from two to eight hours, lithium-ion and sodium-ion chemistry, plus the software and validation work needed to make a battery plant behave when the local grid gets...

Continue Reading
Lake Ridge Sets $0.68 Dividend as 2026 Payouts Rise

Updated Category News Views 155

A community bank raising its cash return is not fireworks, but it gets my attention faster than another glossy growth slogan. Lake Ridge Bancorp has declared a fourth-quarter 2026 dividend of $0.68 per share, payable December 16 to shareholders of record on November 30. That is a plain, useful announcement from OTCQX:LRBI, and plain is often underrated when you are...

Continue Reading
Gildan Lawsuit Puts Revenue Controls Under a Harsh Light

Updated Category News Views 36

Receivables have a nasty way of becoming everybody’s problem once the story cracks. Gildan Activewear is staring at that uncomfortable reality after a securities fraud class action was filed on behalf of investors who bought or acquired shares between February 19, 2025 and June 15, 2026. The case, Cortez v. Gildan Activewear Inc., is pending in the U.S. District Court...

Continue Reading
Roof Leaks Demand Diagnosis Before the Repair Bill

Updated Category News Views 95

A brown ring on a ceiling is often the last witness, not the crime scene. That is the useful, unglamorous point in Jonathan Floyd's HelloNation discussion of roof leaks: water has plenty of ways to move after it slips past a roof's defenses. Homeowners understandably stare at the stain and assume the answer sits directly overhead. Sometimes it does. Plenty of times, it...

Continue Reading
Tigerlily Takes Its Advocacy Model to Ovarian Cancer

Updated Category News Views 126

Ovarian cancer has a nasty habit of hiding behind symptoms people are taught to shrug off. Persistent bloating or pelvic pain can look like any number of ordinary problems, and that ambiguity is exactly why practical, trusted education matters. Tigerlily Foundation's new ovarian cancer initiative is not a flashy breakthrough claim. It is a grounded attempt to help women...

Continue Reading
APEC in Shenzhen Puts Trade Openness Back in Focus

Updated Category News Views 80

Shenzhen is hosting a familiar but consequential argument: prosperity gets harder to share when trade channels clog up. At the 33rd Asia-Pacific Economic Cooperation Economic Leaders' Meeting on November 18, President Xi Jinping used the opening of the APEC CEO Summit to argue for peace, openness, innovation, mutual benefit and support for the WTO-centered multilateral...

Continue Reading
Specialized Metal Makers Become the New M&A Prize Again

Updated Category News Views 14

A forgotten heat-treatment line can suddenly be worth more than a shiny new mill when buyers realize nobody can duplicate its certifications, workforce, and customer approvals overnight. That is the basic truth sitting underneath BGL's Nov. 19, 2026 assessment of the U.S. metals market. The easy headline is consolidation. The useful takeaway is much narrower: specialized...

Continue Reading
Zesty Takes Kubernetes Cost Control Into GPU Territory

Updated Category News Views 18

GPU waste has become the sort of cloud bill nobody wants to explain upstairs. A company buys scarce, expensive accelerators for AI work, then discovers that real workloads do not politely consume resources in neat, permanent blocks. Demand jumps, memory needs shift, and somebody either over-allocates to avoid trouble or under-allocates and gets ugly out-of-memory...

Continue Reading

Top 5 Most Recently Viewed Articles

Telegram Embraces AI and User Transparency Amid Legal Struggles

Updated Category News Views 456

Telegram's Shift Towards Security and Legal Compliance Recently, Telegram's CEO Pavel Durov has announced new measures to improve the platform's adherence to legal requirements, which includes the decision to share user IP addresses and phone numbers with authorities when faced with valid legal requests. This represents a significant departure from Telegram's long-held...

Continue Reading
Lawsuit Against Sable Offshore Accuses Misleading Practices

Updated Category News Views 220

Sable Offshore Faces Legal Actions for Misleading Investors In recent developments, Sable Offshore Corp. (SOC) has been embroiled in a securities class-action lawsuit, claiming that the company deceived investors regarding its oil production activities. This lawsuit, which has drawn significant attention, was filed in federal court and signals serious allegations against...

Continue Reading
Innovative Industrial Properties Investors Face Class Action Deadline

Updated Category News Views 115

Innovative Industrial Properties: Class Action Lawsuit Notification The legal landscape for investors can often seem daunting, particularly when class action lawsuits arise. Recently, Innovative Industrial Properties, Inc. (IIPR) found itself at the center of such a lawsuit, prompting a call to action for affected investors. The law firm Faruqi & Faruqi, LLP, a...

Continue Reading
Hisense Launches HT SATURN Sound System for Home Entertainment

Updated Category News Views 672

Introducing the HT SATURN Home Theatre Sound System In a remarkable step towards redefining home audio systems, Hisense has unveiled the HT SATURN, a cutting-edge 4.1.2?channel surround sound system. This innovative product showcases the exclusive "Tuned by Devialet" certification, ensuring a truly immersive listening experience. The HT SATURN combines Hisense's advanced...

Continue Reading
Groundbreaking Study Shows Benefits of Human Milk Diet for Preemies

Updated Category News Views 510

Revolutionary Findings on Exclusive Human Milk Diet The Impact of Human Milk on Preemie Development A recent study has shed light on the incredible benefits of the Exclusive Human Milk Diet (EHMD) provided by Prolacta Bioscience. This research indicates that premature infants, who typically face numerous developmental challenges due to being born early and less weighty,...

Continue Reading